Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Exploratory Clinical Study of Efbemalenograstim Alfa-vuxw Injection for Primary/Secondary Prevention in Patients With Solid Tumors at High Risk for Febrile Neutropenia (FN) or Intermediate Risk of Chemotherapy Regimens Associated With Other Risk Factors in FN

NCT07187908 is registered in ClinicalTrials.gov with Henan Cancer Hospital as lead sponsor.

NCT NCT07187908
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07187908 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Exploratory Clinical Study of Efbemalenograstim Alfa-vuxw Injection for Primary/Secondary Prevention in Patients With Solid Tumors at High Risk for Febrile Neutropenia (FN) or Intermediate Risk of Chemotherapy Regimens Associated With Other Risk Factors in FN
Lead sponsor
Henan Cancer Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
January 1, 2025
Completion date
October 31, 2027
Enrollment
1,076 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

high risk for febrile neutropenia of chemotherapy regimens, intermediate risk of chemotherapy regimens associated with other risk factors in febrile neutropenia, primary/secondary prevention